High purity excipients for parenteral drug delivery
Parenteral formulation frequently faces limitations associated with drug stability and poor solubility. Drug compatibility and the minimum concentration of drug required to produce the targeted pharmacological effect are key to excipient selection.
Your partner for parenteral formulations:
- Access specialised technical support to navigate and address your formulation challenges
- Explore our extensive offering of high purity, multi-compendial excipients listed by the FDA Inactive Ingredients Database as suitable for parenteral administration
- Our Super RefinedTM products add value to your parenteral drug formulations, reducing API degradation and aiding in successful formulation development.
Reduced API costs for parenteral formulations
Our technical experts have reformulated a range of APIs with our Super Refined excipients, demonstrating a significantly higher percentage of API is retained over time when compared to formulation with standard pharmaceutical grade excipients. Reducing the degradation of your API in formulation lowers your API costs due to a decrease in the minimum efficient concentration required to produce the desired pharmacological effect over the shelf life of your product.
By reducing API degradation, less API is required per dose to reach the efficient concentration to produce the desired pharmacological effect. This not only improves the shelf life of your product but also reduces API costs.
Improving product safety profiles for parenteral delivery
The removal of polar impurities reduces API/excipient interactions, minimising the presence of API degradation products.
Lengthening product shelf lives
Super Refined excipients have been demonstrated to outperform their standard compendial grade counterparts. Our excipients extend the stability of APIs over significantly longer time periods and reduce API oxidation potential – increasing drug stability.
Improving patient comfort for parenteral delivery
Our Super Refined products improve patient comfort through minimising cellular irritation and allergenic reaction potential.
Download the full PDF Injectable Delivery of Small Molecules
or read the article here
Source: Croda, website Parenteral drug delivery | Croda Pharma
Read more on Parental Excipients here:
